PERINATAL ASPHYXIA- WHERE WE ARE TODAY?
DOI:
https://doi.org/10.5457/ams.v45iSuppl.%201.371Abstract
Perinatal asphyxia is the result of interruption of blood flow and gas exchange to the fetus in the perinatal period, and if it is significant, it may trigger a cascade of neuronal injury leading to neonatal encephalopathy and long-term damage. The World Health Organization (WHO) estimates around 3% of 120 million newborns every year in developing countries suffering from perinatal asphyxia, and some 900.000 of these newborns die each year. Hypoxic-ischaemic encephalopathy (HIE) is a major acute neurologic manifestation of perinatal asphyxia, and in severe HIE the mortality rate is reportedly up to 25-50%. Most deaths occur in the first week of life due to multiple organ failure or redirection of care. There has been significant research progress in perinatal asphyxia and consecuent HIE over the last two decades, and many new molecular mechanisms have been identified. Although a different parameters have been used to predict or define perinatal asphyxia no single marker of perinatal asphyxia has shown good predictive efficiency in the early assessment of perinatal asphyxia and its complications. The advent of therapeutic hypothermia as a neuroprotective treatment for those with moderate and severe encephalopathy has improved prognosis. Outcome prediction in these newborns is more important than ever, as hypotermia is a time sensitive intervention, with a very narrow therapeutic window. So, we need to strive to effective, reliable and cheep markers to enable early identifications of newborns at risk of short or long term injury.
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
